Ventyx Biosciences (NASDAQ:VTYX) Issues Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Ventyx Biosciences (NASDAQ:VTYX) posted its quarterly earnings data on Thursday. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.13, Zacks reports.

Ventyx Biosciences Price Performance

Ventyx Biosciences stock opened at $1.58 on Friday. The firm has a market capitalization of $111.72 million, a PE ratio of -0.67 and a beta of 0.52. The company’s 50-day moving average is $1.97 and its 200-day moving average is $2.15. Ventyx Biosciences has a fifty-two week low of $1.41 and a fifty-two week high of $11.48.

Analysts Set New Price Targets

Several equities research analysts recently commented on VTYX shares. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th.

Insider Transactions at Ventyx Biosciences

In related news, insider John Nuss sold 13,161 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $2.26, for a total value of $29,743.86. Following the transaction, the insider now owns 485,701 shares in the company, valued at approximately $1,097,684.26. This represents a 2.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sheila Gujrathi purchased 130,000 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the purchase, the director now owns 130,000 shares in the company, valued at $300,300. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 18.18% of the stock is owned by company insiders.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.